Remission of Acromegaly: The Sooner the Better
Remission of acromegaly is defined by normalization of GH/IGF-1 values according to age and gender. While treatment strategies, biochemical cut-off to reach, and morbidities related to the persistence of the disease are well described in the literature, there is little data focusing on the delay to reach remission and its consequences. In this commentary, the authors discussed the results obtained from the UK acromegaly registry showing that the time to biochemical remission predicts the overall survival of patients in acromegaly.
Authors
- Luigi Maione (ORCID: https://orcid.org/0000-0001-8526-8046)
- Sylvère Störmann (ORCID: https://orcid.org/0000-0002-5465-3491)
- Thomas Cuny (ORCID: https://orcid.org/0000-0002-8440-0030)
Institutions
- Inserm (FR)
- Aix-Marseille Université (FR)
- Université Paris-Saclay (FR)
- LMU Klinikum (DE)
- Hôpital de la Conception (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Bicêtre Hospital (FR)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Clinical Endocrinology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1111/cen.15147
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00